Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Myeloid/lymphoid neoplasm with FGFR1 rearrangement Indication Strategy Report 2026: FGFR1, Trials and Deals
30 July 2026
2026 Myeloid/lymphoid neoplasm with FGFR1 rearrangement indication strategy covering epidemiology, FGFR1 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Acute erythroid leukemia Indication Strategy Report 2026: BCL2, Trials and Deals
30 July 2026
2026 Acute erythroid leukemia indication strategy covering epidemiology, BCL2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Acute megakaryoblastic leukemia Indication Strategy Report 2026: MPL, Trials and Deals
30 July 2026
2026 Acute megakaryoblastic leukemia indication strategy covering epidemiology, MPL biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Breast implant-associated anaplastic large cell lymphoma Indication Strategy Report 2026: CD30, Trials and Deals
30 July 2026
2026 Breast implant-associated anaplastic large cell lymphoma indication strategy covering epidemiology, CD30 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Monomorphic epitheliotropic intestinal T-cell lymphoma Indication Strategy Report 2026: JAK-STAT, Trials and Deals
30 July 2026
2026 Monomorphic epitheliotropic intestinal T-cell lymphoma indication strategy covering epidemiology, JAK-STAT biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Splenic B-cell lymphoma with prominent nucleoli Indication Strategy Report 2026: BRAF, Trials and Deals
30 July 2026
2026 Splenic B-cell lymphoma with prominent nucleoli indication strategy covering epidemiology, BRAF biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
Hairy cell leukemia variant Indication Strategy Report 2026: BRAF, Trials and Deals
30 July 2026
2026 Hairy cell leukemia variant indication strategy covering epidemiology, BRAF biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Subcutaneous panniculitis-like T-cell lymphoma Indication Strategy Report 2026: HAVCR2, Trials and Deals
30 July 2026
2026 Subcutaneous panniculitis-like T-cell lymphoma indication strategy covering epidemiology, HAVCR2 biology, active trials, transactions, unmet need,…
Latest Hotspot
8 min read
B-cell prolymphocytic leukemia Indication Strategy Report 2026: BCL2, Trials and Deals
30 July 2026
2026 B-cell prolymphocytic leukemia indication strategy covering epidemiology, BCL2 biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
T-cell prolymphocytic leukemia Indication Strategy Report 2026: TCL1A, Trials and Deals
30 July 2026
2026 T-cell prolymphocytic leukemia indication strategy covering epidemiology, TCL1A biology, active trials, transactions, unmet need, competition and market…
Latest Hotspot
8 min read
Primary cutaneous gamma delta T-cell lymphoma Indication Strategy Report 2026: JAK1, Trials and Deals
30 July 2026
2026 Primary cutaneous gamma delta T-cell lymphoma indication strategy covering epidemiology, JAK1 biology, active trials, transactions, unmet need, competition…
Latest Hotspot
8 min read
Intraocular lymphoma Indication Strategy Report 2026: BTK, Trials and Deals
30 July 2026
2026 Intraocular lymphoma indication strategy covering epidemiology, BTK biology, active trials, transactions, unmet need, competition and market attractiveness.